Filing Details
- Accession Number:
- 0001127602-13-029672
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-10-23 17:03:15
- Reporting Period:
- 2013-10-22
- Filing Date:
- 2013-10-23
- Accepted Time:
- 2013-10-23 17:03:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875045 | Biogen Idec Inc. | BIIB | Biological Products, (No Disgnostic Substances) (2836) | 330112644 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1577061 | Alfred Sandrock | Biogen Idec Inc. 133 Boston Post Rd. Weston MA 02493 | Grp Svp, Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-10-22 | 15,030 | $60.56 | 29,530 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-10-22 | 15,030 | $250.11 | 14,500 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-10-22 | 15,030 | $0.00 | 15,030 | $60.56 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2018-02-12 | No | 4 | M | Direct |
Footnotes
- Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- This represents the weighted average price for shares sold at a range between $250.00 (low) and $250.28 (high).
- Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- The stock options became exercisable in four (4) equal annual installments commencing one year after the grant date of 02/12/08.